ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 868

International Multi-Reader Validation of the Outcome Measures in Rheumatology Hip MRI Scoring System (OMERACT HIMRISS) for Bone Marrow Lesions in Osteoarthritis

Jacob L. Jaremko1, Robert G. Lambert2, Susanne J Pedersen3, Ulrich Weber4, Duncan Lindsay5, Zeid Al-Ani5, Marcus Pianta6, Stephanie Wichuk7, Kieran Steer8, Joel Paschke9 and Walter P. Maksymowych10, 1Radiology, University of Alberta, Edmonton, Canada, Edmonton, AB, Canada, 2Radiology, Radiology, University of Alberta, Edmonton, AB, Canada, 3Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 4University of Southern Denmark, Odense, Denmark, 5Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, 6Rheumatology, St. Vincent's Hospital, Melbourne, Australia, 7Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, 8Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, 9CaRE Arthritis, Edmonton, Canada, Edmonton, AB, Canada, 10CaRE Arthritis, Edmonton, AB, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: MRI and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S082 ACR Abstract: Imaging of Rheumatic Diseases I: MRI & CT (863–868)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Bone marrow lesion (BML) in hip osteoarthritis (OA) may be a determinant of prognosis and a target for emerging anti-inflammatory therapies. We developed the OMERACT Hip MRI Scoring System (HIMRISS) to maximize reliability & sensitivity to change. Innovations include electronic overlays (touch or mouse-click a region to identify BML), a web-based online interface, and real-time iterative calibration (RETIC) in which new readers perform a scoring exercise online, learning by observing their ICC vs. expert consensus displayed in real-time. Pre-specified minimum ICC must be achieved before becoming eligible to proceed with formal scoring. We tested feasibility, reliability, and responsiveness of HIMRISS for scoring BML in a large prospective cohort.

Methods:

In HIMRISS, BML is scored as 0/1 (absent/present) in 100 regions on a web-based grid overlay slice-by-slice in coronal hip MRI. In the Edmonton Steroid Injection in Hip OA (STIHO) cohort, we had n=90 patients x 2 hips x 2 MRI: at baseline presenting for hip steroid injection, and at 8 weeks post injection. Coronal T1/STIR sequences were provided, blinded to time point, to 8 readers: 2 radiology fellows, 3 rheumatologists, 3 musculoskeletal radiologists. Each reader prepared by reviewing a comprehensive HIMRISS methodology module, then had to pass an online RETIC training module with proficiency (ICC 0.80 vs. experts) prior to formal scoring. Readers each scored HIMRISS BML in all 360 hips.

Results:

Subjects were 56% male, age 59±13 (mean±SD) years, symptom duration 4.4±4.5 years, K-L OA grade 1/2/3/4 in 20%/28%/34%/18%. Reliability (ICC single measure, absolute agreement, 2 way model) was high for baseline BML status for all readers (0.83) and for 2 experts (0.88-0.92). Change was small, mean (SD) 2.1±10.0/100. Despite this, ICC for change was (0.42-0.76) for all readers, (0.56-0.81) for experts.

Conclusion:

HIMRISS reliably quantifies BML in hip OA at a single time point and can responsively discriminate small changes in BML. Novice readers trained via an online RETIC system achieved reliability close to that of experts. Future studies will assess performance of HIMRISS assessing inflammation in other arthropathies.

Reliability of HIMRISS BML Measurements

Baseline Status

Change

ICC for BML

All readers

Experts

All readers

Experts

Femoral head

0.83 (0.65-0.91)

0.91 (0.87-0.94)

0.76 (0.65-0.83)

0.81 (0.72-0.87)

Acetabulum

0.83 (0.74-0.89)

0.88 (0.82-0.92)

0.42 (0.23-0.57)

0.56 (0.40-0.68)

Total

0.83 (0.55-0.92)

0.92 (0.88-0.95)

0.72 (0.60-0.81)

0.78 (0.68-0.85)

Change in BML, and HIMRISS Responsiveness

Scoring range

Change observed 0-8 wks; mean(SD)

Smallest detectable change SDC

Hips with change >SDC

Femoral head

0-65

2.2(9.2)

3.6

45%

Acetabulum

0-35

-0.1(2.3)

1.9

33%

Total

0-100

2.1(10.0)

4.6

36%


Disclosure: J. L. Jaremko, None; R. G. Lambert, None; S. J. Pedersen, None; U. Weber, None; D. Lindsay, None; Z. Al-Ani, None; M. Pianta, None; S. Wichuk, None; K. Steer, None; J. Paschke, None; W. P. Maksymowych, CaRE rthritis, 9.

To cite this abstract in AMA style:

Jaremko JL, Lambert RG, Pedersen SJ, Weber U, Lindsay D, Al-Ani Z, Pianta M, Wichuk S, Steer K, Paschke J, Maksymowych WP. International Multi-Reader Validation of the Outcome Measures in Rheumatology Hip MRI Scoring System (OMERACT HIMRISS) for Bone Marrow Lesions in Osteoarthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/international-multi-reader-validation-of-the-outcome-measures-in-rheumatology-hip-mri-scoring-system-omeract-himriss-for-bone-marrow-lesions-in-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/international-multi-reader-validation-of-the-outcome-measures-in-rheumatology-hip-mri-scoring-system-omeract-himriss-for-bone-marrow-lesions-in-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology